Abstract:Although a majority of women with high-grade serous ovarian cancer (HGSC) achieve a complete response to first-line platinum- and paclitaxel-based chemotherapy, around thirty percent of patients are identified as incomplete responders. Their diseases typically either does not respond or progresses during treatment (refractory) or recurs within 6 months of completing treatment (resistant), suggesting the inherit or intrinsic characteristics of the tumor. Currently, there are no biomarkers that can predict intrinsic resistance, which can avoid unnecessary treatment and toxicity. MicroRNAs (miRNAs) provide a novel master layer of regulation of gene expression. However, the molecular mechanisms by which miRNAs confer a chemoresistant phenotype in ovarian cancer have not been elucidated. To identify miRNAs that are associated with intrinsic chemoresistance in HGSC, Ion Torrent next-generation sequencing analysis of miRNAs was performed on microdissected chemosensitive and chemorefractory primary HGSC cases. Amongst all the miRNAs that were significantly down-regulated in chemorefractory cases, lower miR-625-3p expression was found to be associated with poorer overall and progression-free survivals. Further functional studies showed that overexpression of miR-625-3p significantly decreased cisplatin and paclitaxel resistance in ovarian cancer cells in vitro and in vivo. Online target prediction algorithms together with transcriptome profiling of HGSC cells transfected with miR-625-3p mimics or control mimics identified SSX2IP as a direct target of miR-625-3p, suggesting that SSX2IP may play a role in conferring cisplatin/paclitaxel resistance in HGSC by mediating the effect of miR-625-3p. SSX2IP is a microtubule anchoring and centriolar satellite protein, which plays a critical role in controlling microtubule length and orientation, and centrosome maturation. We demonstrated that HGSC cells transfected with SSX2IP had marked increases in microtubule masses, intracellular multivesicular body trafficking and exosomal cisplatin level; and a decrease in intracellular cisplatin level. In conclusion, down-regulation of miR-625-3p confers cisplatin/paclitaxel resistance in ovarian cancer cells via its novel direct target SSX2IP. SSX2IP alters the microtubule dynamics and subsequently mediates inter-organelle crosstalks between microtubules and multivesicular bodies, which facilitate exosomal export of cisplatin and paclitaxel of HGSC cells. This study is crucial for developing new predictive biomarkers for intrinsic chemoresistance, and new treatment strategies for HGSC based on upregulating miR-625-3p or downregulating SSX2IP expression in ovarian cancer cells, which will enhance cisplatin and paclitaxel sensitivity, and improve patient survival rates. Citation Format: Chi Lam Au Yeung, Tetsushi Tsuruga, Kay-Pong Yip, Sammy Ferri-Borgogno, Samuel Mok. miR-625-3p enhances chemosensitivity in ovarian cancer cells through exosomal export of cisplatin and paclitaxel [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 1551.

Abstract 3762: Downregulation of TRPC3 Enhances Sensitivity to Cisplatin and Inhibits Motility in Epithelial Ovarian Cancer

Targeting RPL23 restores chemosensitivity of cisplatin-resistant ovarian carcinoma by inhibiting EMT

Chemokine CXCL-2 Regulates Resistance to Platinum in Epithelial Ovarian Cancer by Mediating ATR/CHK1 Signaling Pathway

Chemokine CX3CL1/CX3CR1 biological axis promote ovarian cancer cell apotosis induced by platinum drug

miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells

CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer

Cisplatin Remodels the Tumor Immune Microenvironment Via the Transcription Factor EB in Ovarian Cancer

Down-regulation of Ras-related Protein Rab 5C-Dependent Endocytosis and Glycolysis in Cisplatin-resistant Ovarian Cancer Cell Lines

Abstract A033: The transcriptional landscape of cisplatin resistance and its relationship with epithelial mesenchymal transition in ovarian cancer

CYLD and HER3 Regulate Platinum Resistance in Ovarian Cancer via Drug Efflux Pump ABCB1

Downregulation of Transient Receptor Potential Cation Channel, Subfamily C, Member 1 Contributes to Drug Resistance and High Histological Grade in Ovarian Cancer.

Deregulation of Exo70 Facilitates Innate and Acquired Cisplatin Resistance in Epithelial Ovarian Cancer by Promoting Cisplatin Efflux

Abstract 4540: Follicle-stimulating Hormone (FSH) Enhances the Proliferation of Epithelial Ovarian Cancer Cells by Activating Transient Receptor Potential Channel C3 (TRPC3)

Correction For: CXCR4 Knockdown Enhances Sensitivity of Paclitaxel Via the PI3K/Akt/mTOR Pathway in Ovarian Carcinoma.

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer

Protein Tyrosine Phosphatase PTPN3 Promotes Drug Resistance and Stem Cell-Like Characteristics in Ovarian Cancer

Abstract 1551: miR-625-3p enhances chemosensitivity in ovarian cancer cells through exosomal export of cisplatin and paclitaxel

Low Expression of MYCN Promotes Cisplatin Resistance by Suppressing Cisplatin-Induced Apoptosis in Epithelial Ovarian Cancer.

Cx32 Mediates Cisplatin Resistance in Human Ovarian Cancer Cells by Affecting Drug Efflux Transporter Expression and Activating the EGFR‑Akt Pathway

Protein Tyrosine Phosphatase Receptor Type Z1 Inhibits the Cisplatin Resistance of Ovarian Cancer by Regulating PI3K/AKT/mTOR Signal Pathway.

eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27 Kip1 translation